- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03423784
Performance and Tolerability of a New Medical Device Gel, a Randomized, Open Label, Parallel-group, Multicentre Study
May 14, 2018 updated by: Opera CRO, a TIGERMED Group Company
Performance and Tolerability of a New Medical Device Coating Gel for the Temporary Relief of Teething Symptoms: a Randomized, Open Label, Parallel-group, Multicentre Study
Medical device study for efficacy and tolerability of a HA gel in the management of teething symptoms
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Due to the potential toxicity that can result from the use of topical anesthetics to relieve the symptoms associated with gingival inflammatory conditions or gums trauma in infant, recently, products containing Hyaluronic Acid (HA) have been marketed in Europe.
In particular, Bioplax Limited is developing several high molecular weight HA medical devices characterized by the absence of preservatives, alcohol and dyes; therefore, the administration of these products in infants is safe and can help creating a natural protective layer on the gingival tissue.
In previous clinical trials with these high molecular weight HA medical devices it was noted a periodontal tissue/fluid balance with accelerated healing and repair properties that could be of interest either for accelerating the wound healing process or for treating the complex physical symptoms (i.e.
soreness and swelling of gums, crying, sleeplessness) related to the teething in infants.
These data were confirmed by a recent pilot study on 18 infants suffering by teething where the two formulation of the tested high molecular weight HA medical device evidenced, at the end of treatment period, a statistically significant reduction of pain, swelling, gingival rush, hyper-salivation and redness, from baseline.
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 months to 3 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female infants aged between 3 and 36 months.
Teething diagnosed by the presence of at least 3 of the following clinical symptoms:
- pain
- swelling
- hyper-salivation
- redness
- abnormal teeth depth.
- At the moment of inclusion no subcutaneous mucosal laceration must be yet appeared.
- Infants and parents who are in a general position to follow all study requirements.
- Informed consent form signed by parents or legal representative.
Exclusion Criteria:
- Infants in hospitalization and/or immobilization and/or confinement to bed.
- Infants with known history of severe renal insufficiency and/or known history of severe cardiac dysfunction and/or liver problems.
- Use of topical oral Lidocaine, other topical oral anesthetic products and/or topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within one day before inclusion.
- Use of systemic NSAIDs within 3 days before inclusion and/or use of systemic anesthetics within 10 days before.
- Concomitant use during the period of study of NSAIDs and/or any other anesthetics (except Dentinox®-Gel N, for subjects allocated to group II of treatment).
- Subjects with known family history of allergic or adverse reactions to drugs or substances.
- Infants whose parents suffer from any form of psychiatric disorder or other condition which, in the opinion of the Investigator, might invalidate the required prescription and/or observation or complicate communication with the subject.
- Infants simultaneously participating or having participated in the last month before Visit 1 in another clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HA BPX V3.3
A HMWHA gel available in a formulation specificaly designed for use in infants
|
medical device containing HA
|
Active Comparator: Dentinox-Gel N
Gold standard for teething symptoms
|
Anaesthetic gel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in gingival swelling
Time Frame: 3 days
|
Face, Legs, Activity, Cry and Consolability Pain Assesment Scale
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in crying
Time Frame: 7 days
|
Face, Legs, Activity, Cry and Consolability Pain Assesment Scale
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Rosu Serban, MD, SCM Dr. Rosu
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2013
Primary Completion (Actual)
March 31, 2015
Study Completion (Actual)
June 30, 2015
Study Registration Dates
First Submitted
January 26, 2018
First Submitted That Met QC Criteria
February 5, 2018
First Posted (Actual)
February 6, 2018
Study Record Updates
Last Update Posted (Actual)
May 17, 2018
Last Update Submitted That Met QC Criteria
May 14, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BPX11-13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tooth Disease
-
Hereditary Neuropathy FoundationRecruitingCharcot-Marie-Tooth Disease | Charcot-Marie-Tooth Disease, Type IA | Charcot-Marie-Tooth Disease Type 2A | Charcot-Marie-Tooth | Charcot-Marie-Tooth Disease, Type IB | Charcot-Marie-Tooth Disease Type 2 | Charcot-Marie-Tooth Disease, Type 2C | Charcot-Marie-Tooth Disease Type 2A2B | Charcot-Marie-Tooth... and other conditionsUnited States
-
National Institute of Dental and Craniofacial Research...RecruitingTooth Diseases | Diseases | Tooth | Stomatognatic | Tooth ImpactionUnited States
-
Hacettepe UniversityActive, not recruiting
-
Shanghai Ninth People's Hospital Affiliated to...Active, not recruiting
-
Hacettepe UniversityCompleted
-
Shanghai Ninth People's Hospital Affiliated to...Completed
-
Hacettepe UniversityRecruiting
-
Hacettepe UniversityActive, not recruiting
-
Shanghai Ninth People's Hospital Affiliated to...Completed
Clinical Trials on HA BPX V3.3
-
Bellicum PharmaceuticalsActive, not recruitingLymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Myelogenous LeukemiaUnited States
-
BioPharmX, Inc.CompletedAcne VulgarisUnited States
-
BioPharmX, Inc.Completed
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Bellicum PharmaceuticalsWithdrawnRecurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic... and other conditionsUnited States
-
Bellicum PharmaceuticalsTerminatedAcute Myeloid Leukemia | Myelodysplastic Syndrome | Uveal MelanomaUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsActive, not recruitingLymphoma | Myelodysplastic Syndromes | Leukemia | Hematologic Neoplasms | Multiple MyelomaUnited States
-
Bellicum PharmaceuticalsTerminatedHemoglobinopathies | Hemophagocytic Lymphohistiocytosis | Metabolic Disorders | Primary Immune Deficiency Disorders | Inherited Bone Marrow Failure SyndromeUnited States
-
Bellicum PharmaceuticalsWithdrawnHematologic MalignanciesUnited States
-
BioPharmX, Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States